Compare Adaptive Biotechnologies Corp (ADPT) vs International Business Machines Corp (IBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs International Business Machines Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while International Business Machines Corp trades at $301.18 (market cap $287.73B). The key difference: International Business Machines Corp is far larger — about 86.4× Adaptive Biotechnologies Corp's market cap, and International Business Machines Corp pays a 2.21% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | IBM | |
|---|---|---|
Market Cap | $3.33B | $287.73B |
Sector | Health | Technology |
52-Week High | $22.37 | $329.23 |
52-Week Low | $10.24 | $214.64 |
Enterprise Value | $3.19B | $345.75B |
Volume | — | 4,481,527 |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
IBM's stock trades at $306.13, up 5.74% today, and is near its consensus price target of $308.14. The technical outlook is bullish with strong moving average signals, though the 6-day RSI indicates overbought conditions. Fundamentally, the company reported revenue of $67.54B in 2025 with a net income margin of 15.61%, and it has beaten earnings estimates for the last three quarters. Recent news highlights product launches in AI and quantum computing.
The outlook is positive with continued earnings momentum and strategic focus on high-growth areas like AI and hybrid cloud. Key risks include competitive pressures in technology and execution challenges in innovation. Analyst sentiment is mixed but leans bullish, with 47% buy ratings. The stock offers a dividend yield supported by strong cash flow from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
